Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★

Ran Reshef(Abramson Cancer Center), Daniel Tsai(University of Pennsylvania), Daniel F. Heitjan(Southern Methodist University), Edward A. Stadtmauer(University of Pennsylvania), Denis Hadjiliadis(University of Pennsylvania), Lee R. Goldberg(University of Pennsylvania), Karen Krok(University of Pennsylvania), Saran Vardhanabhuti, Simin Göral(University of Pennsylvania), David Porter(University of Pennsylvania), Marlise R. Luskin(Dana-Farber Cancer Institute)
American Journal of Transplantation
January 10, 2011
10.1111/j.1600-6143.2010.03387.x
Cited by 218

Related Papers

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
|Blood|2010|477
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441